Market Trend Analysis: The Impact of Recent Developments on the ACE Inhibitors Market

The ACE inhibitors market is on track for impressive growth as healthcare continues to evolve. Innovations in medicine, expanding digital solutions, and rising demand for personalized treatments are driving this sector forward. Below, we explore the market's projected size, key players, emerging trends, and the various market segments shaping its future.

Forecasted Growth and Market Size of the ACE Inhibitors Industry
The ACE inhibitors market is expected to reach a value of $10.11 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.5%. This upward trajectory is fueled by growing interest in personalized medicine approaches, the integration of digital health technologies, increased penetration in emerging markets, the development of innovative ACE inhibitor combinations, and a rise in home healthcare services. Key trends likely to influence this growth include personalized hypertension management, telemedicine and remote patient monitoring, advancements in combination therapies, a surge in generic ACE inhibitors, and broader adoption of home care solutions.

Download a free sample of the ace inhibitors market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Prominent Companies Influencing the ACE Inhibitors Market
The competitive landscape of the ACE inhibitors market features several leading pharmaceutical firms such as Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus Lifescience Ltd., and Apotex Inc.

Significant Acquisition to Enhance Product Pipeline
In January 2023, AstraZeneca, headquartered in the UK, completed the acquisition of CinCor Pharma for $1.3 billion. This strategic move is intended to broaden AstraZeneca's portfolio of aldosterone synthase inhibitors (ASI) aimed at managing treatment-resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, is focused on novel therapies targeting resistant and uncontrolled hypertension as well as chronic kidney diseases, supporting AstraZeneca's efforts to address unmet medical needs.

View the full ace inhibitors market report:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Trends Pushing the ACE Inhibitors Market Forward
Pharmaceutical companies in this space are increasingly prioritizing the launch of generic ACE inhibitor medications to remain competitive and offer cost-effective solutions. Generic drugs contain the same active ingredients, dosage, safety profile, and efficacy as the original branded products but are generally available at a lower price once patents expire.

A case in point, in August 2023, Canadian pharma firm Pharmascience Inc. introduced pms-PERINDOPRIL-INDAPAMIDE, a generic combination for treating mild to moderate essential hypertension in adults. This product blends perindopril erbumine, an ACE inhibitor that helps relax blood vessels, with indapamide, a diuretic that removes excess fluid and sodium. The synergy between these components effectively lowers blood pressure for diverse patient groups. The medication offers multiple dosage options, including 2 mg, 4 mg, and 8 mg of perindopril erbumine paired with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide.

Comprehensive Segmentation of the ACE Inhibitors Market
This report categorizes the ACE inhibitors market into detailed segments to provide a clear understanding of the industry:

1) By Type:
- Sulfhydryl-containing Agents
- Dicarboxylate-containing Agents
- Phosphonate-containing Agents

2) By Drug:
- Ramipril
- Enalapril
- Benazepril
- Fosinopril
- Captopril
- Moexipril
- Other Drugs

3) By Dosage Form:
- Oral Tablets
- Oral Solutions

4) By Application:
- Heart Failure
- Chronic Kidney Disease
- Hypertension
- Diabetes
- Heart Attack
- Other Applications

5) By End-Users:
- Hospitals
- Online Drug Stores
- Other End-Users

Further subcategories include:
- Sulfhydryl-Containing Agents: Captopril, Zofenopril
- Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
- Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium

These classifications help map out the market comprehensively, highlighting the diversity of products, applications, and consumer bases within the ACE inhibitors sector.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.